The oral therapy Jascayd (nerandomilast) has been approved in Europe for adults with idiopathic pulmonary fibrosis and ...

Columnist Sam Kirton recounts his recent 17-day stay at Inova Fairfax Hospital after receiving a diagnosis of shingles.

Not being able to help with farm chores since her pulmonary fibrosis diagnosis has been a difficult adjustment for columnist ...

While oxygen therapy does not directly address the underlying cause of pulmonary fibrosis or halt the progression of the disease, it is an important therapy that improves symptoms and organ function.

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Trevi Therapeutics plans to launch two pivotal Phase 3 clinical trials to continue testing Haduvio (nalbuphine extended-release) as a treatment for people with idiopathic pulmonary fibrosis (IPF) who ...

The U.S. Food and Drug Administration (FDA) has approved a generic version of Ofev (nintedanib) for easing lung scarring in people with idiopathic pulmonary fibrosis (IPF). The new generic nintedanib ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Amy Silverstein’s second memoir, “My Glory Was I Had Such Friends” (2017), left a lasting impression on me. It wasn’t just because of the way Silverstein’s devoted friends attended to her while she ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...